Supernus Pharmaceuticals reported $0 in Loan Capital for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Loan Capital Change
Aerie Pharmaceuticals AERI:US $ 312.13M 0.45M
Aurora Cannabis Inc ACB:CN 343.55M 26.3M
Bristol Myers Squibb BMY:US $ 37107M 343M
Canopy Growth Corp WEED:CN C$ 1.26B 270.14M
Cara Therapeutics CARA:US $ 0 0
Corcept Therapeutics CORT:US $ 0M 0M
Eisai 4523:JP Y 84905M 9988M
Eli Lilly And LLY:US $ 14692M 460.9M
Horizon Pharma HZNP:US $ 2550.99M 1.75M
JAZZ PHA JAZZ:US $ 5990M 2.87M
Lannett LCI:US $ 610.08M 6.6M
Marinus Pharmaceuticals MRNS:US $ 70.35M 0.42M
Pacira Pharmaceuticals PCRX:US $ 721.88M 7.86M
Perrigo Ordinary Shares PRGO:US $ 4086.1M 575.5M
Revance Therapeutics RVNC:US $ 378.38M 52.48M
Supernus Pharmaceuticals SUPN:US $ 0M 400.38M
Teva Pharmaceutical Industries TEVA:US $ 20363M 477M
United Therapeutics UTHR:US $ 800M 0M
Xeris Pharmaceuticals Inc XERS:US $ 138.07M 429K